Molecular and Cellular Biochemistry

, Volume 176, Issue 1–2, pp 47–51 | Cite as

Smooth muscle contractility and protein tyrosine phosphorylation

  • Ashok K. Srivastava
  • Jean St-Louis


During the last 5 years several studies have documented an involvement of protein tyrosine kinases (PTKs) in smooth muscle contraction and Ca2+mobilization. Most of these studies have utilized highly selective inhibitors of PTKs, genistein and tyrphostin and have shown that these inhibitors attenuated smooth muscle contraction induced by growth factors - epidermal growth factor (EGF) and platelet derived growth factor (PDGF) and several vasoactive peptides. It has also been demonstrated that inhibitors of protein tyrosine phosphatases (PTPases) such as vanadate and pervanadate mimic growth factors and vasoactive peptides in causing the contraction of smooth muscle. In this brief review, we have summarized some of the recent observations suggesting a possible link between protein tyrosine phosphorylation pathway and smooth muscle contraction.

tyrosine kinases growth factors vanadate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Somylo AP, Somlyo AV: Signal transduction and regulation in smooth muscle. Nature 372: 232–236, 1994Google Scholar
  2. 2.
    Kamm KE, Stull JT: Regulation of smooth muscle contractile elements by second messengers. Ann Rev Physiol 51: 299–314, 1989Google Scholar
  3. 3.
    Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K: Regulation of myosine phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273: 245–248, 1996Google Scholar
  4. 4.
    Yang S-G, Saifeddine M, Hollenberg MD: Tyrosine kinase inhibitors and the contractile action of epidermal growth factor urogastrone and other agonists in gastric smooth muscle. Can J Physiol Pharmacol 70: 85–93, 1992Google Scholar
  5. 5.
    Sauro MD, Thomas B: Tyrphostin attenuates platelet-derived growth factros-induced contraction in smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Expt Therapeut 267: 1119–11254, 1993Google Scholar
  6. 6.
    Saifeddine M, Laniyonu A, Yang S-G, Hollenberg MD: Tyrosine kinase inhibitors and the contractile actions of angiotensin II in vascular tissue. Pharmacol Commun 1: 177–184, 1992Google Scholar
  7. 7.
    Yang S-G, Saifeddine M, Laniyonu A, Hollenberg MD: Distinct signal transduction pathways for angiotensin II in guinea pig gastric smooth muscle: Differential blockade by indomethacin and tyrosine kinase inhibitors. J Pharm Exptl Ther 264: 958–967, 1993Google Scholar
  8. 8.
    Sauro MD, Sudakow R, Burns S: In vivo effects of angiotensin II on vascular smooth muscle contraction and blood pressure are mediated through a protein tyrosine kinase-dependent mechanism. J Pharmacol Exptl Therap 277: 1744–1750, 1996Google Scholar
  9. 9.
    DiSalvo J, Steusloff A, Semenchuk L, Satoh S, Koloquist K, Pfitzer G: Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle. Biochem Biophys Res Commun 190: 968–974, 1993Google Scholar
  10. 10.
    Laniyone AA, Saifeddine M, Yang SG, Hollenberg MH: Tyrosine kinase inhibitors and the contractile action of G-protein-linked vascular agonists. Can J Physiol Pharmacol 72: 1075–1085, 1994Google Scholar
  11. 11.
    Hollenberg MD: Tyrosine kinase pathways and the regulation of smooth muscle contractility. Trends in Pharmacol Sci 15: 108–114, 1994Google Scholar
  12. 12.
    Toma C, Jensen PE, Prieto D, Hughes A, Mulvany MJ, Aalkjaer C: Effect of tyrosine kinase inhibitors on the contractility of rat mesenteric resistance arteries. Br J Pharmacol 114: 1266–1272, 1995Google Scholar
  13. 13.
    Hollenberg MD: The actions of growth factors in smooth muscle systems. Life Sciences 54: 223–235, 1993Google Scholar
  14. 14.
    Wjetunge S, Aalkjaer C, Schachter M, Hughes AD: Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun 181: 1620–1623, 1992Google Scholar
  15. 15.
    Lee K-M, Toscas K, Villereal ML: Inhibition of bradykinin-and thapsigargin-induced Ca 2+ entry by tyrosine kinase inhibitors. J Biol Chem 268: 9945–9948, 1993Google Scholar
  16. 16.
    Semenchuk LA, DiSalvo J: Receptor activated increase in intracellular calcium and protein tyrosine phosphorylation in vascular smooth muscle cells. FEBS Lett 370: 127–130, 1995Google Scholar
  17. 17.
    Kaplan N, DiSalvo J: Coupling between [Arginine8 ]-vasopressin-activated increases in protein tyrosine phosphorylation and cellular calcium in A7 X5 aortic smooth muscle cells. Arch Biochem Biophys 270–280, 1996Google Scholar
  18. 18.
    Touyz RM, Schiffrin EL: Tyrosine kinase signaling pathways modulate angiotensin II-induced ([Ca 2+ ];) transients in vascular muscle cells. Hypertension 27: 1097–1103, 1996Google Scholar
  19. 19.
    Moolenaar WH, Tertoolen LGJ, deLaat SW: Growth factors immediately raise cytoplasmic free Ca 2+ in human fibroblasts. J Biol Chem 259: 8066–8069, 1984Google Scholar
  20. 20.
    Morris JD, Metcalfe JC, Smith GA, Hesketch TR, Taylor MU: Some mitogens cause rapid increases in free calcium in fibroblasts. FEBS Lett 169: 189–193, 1984Google Scholar
  21. 21.
    Berk BC, Brock TA, Webb RC, Taubman MB, Atkinson WJ, Gimbrone MA Jr, Alexander RW: Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin In-vest 75: 1083–1086, 1985Google Scholar
  22. 22.
    Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC: Vasoconstriction: a new activity for platelet derived growth factor. Science 232: 87–90, 1986Google Scholar
  23. 23.
    Ullrich A, Schlessinger J: Signal transduction by receptors with tyro-sine kinase activity. Cell 61: 203–212, 1990Google Scholar
  24. 24.
    Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kineses. J Biol Chem 262: 5592–5595, 1987Google Scholar
  25. 25.
    Levitzki A, Gilon C: Tyrphostins as molecular tools and potential therapeutic drugs. Trends Pharmacol Sci 12: 171–174, 1991Google Scholar
  26. 26.
    Ozaki H, Urakawa N: Effect of vanadate on mechanical responses and Na-K pump in vascular smooth muscle. Eur J Pharmacol 68: 339–347, 1980Google Scholar
  27. 27.
    Shimada T, Shimamura K, Sunano S: Effects of sodium vanadate on various types of vascular smooth muscles. Blood Vessels 23: 113–124, 1986Google Scholar
  28. 28.
    Sanchez-Ferrer CF, Marln J, Lluch M, Valverde A, Salaiees M: Actions of vanadate on vascular tension and sodium pump activity in cat isolated cerebral and femoral arteries. Br J Pharmacol 93: 53–60, 1988Google Scholar
  29. 29.
    Hudgins PM, Bond GH: Alteration by vanadate of contractility in vascular and intestinal smooth muscle preparations. Pharmacology 23: 156–164, 1981Google Scholar
  30. 30.
    Nayler RA, Sparrow MP: Mechanism of vanadate-induced contraction of airways smooth muscle of the guinea-pig. Br J Pharmacol 80: 163–172, 1983Google Scholar
  31. 31.
    Sunano S, Kato S, Moriyama K, Shimamura K: Influences of sodium on the contractile action of vanadate in depolarized vas deferens and ureter of the guinea-pig. Arch Int Pharmacodyn Therap 293: 196–208, 1988Google Scholar
  32. 32.
    Candura SM, Manzo L, Marraccini P, Coccini T, Tonini M: Investigation into vanadate-induced potentiation of smooth muscle contractility in the rabbit isolated ileum. Life Sci 54: 237–244, 1993Google Scholar
  33. 33.
    Swarup G, Cohen S, Garbers DL: Inhibition of membrane phospho-tyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun 107: 1104–1109, 1982Google Scholar
  34. 34.
    DiSalvo J, Semenchuk LA, Lauer J: Vanadate-induced contraction of smooth muscle and enhanced protein tyrosine phosphorylation. Arch Biochem Biophys 304: 386–391, 1993Google Scholar
  35. 35.
    St-Louis J, Sicotte B, Breton E, Srivastava AK: Vanadate-induced smooth muscle contraction and protein tyrosine phosphorylation is impaired in pregnancy. J Mol Cell Cardiol 27: 104 (abstract), 1995Google Scholar
  36. 36.
    Posner BI, Faure R, Burgess JW, Beavan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxo-vanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596–4604, 1994Google Scholar
  37. 37.
    Laniyonu A, Saifeddin M, Ahmad S, Hollenberg MD: Modulation of vascular and smooth muscle contractility by pervanadate. Brit J Pharmacol 113: 403–410, 1994Google Scholar
  38. 38.
    St-Louis J, Sicotte B, Breton E, Srivastava AK: Contractile effects of vanadate on aorta rings from virgin and pregnant rats. Mol Cell Biochem 153: 145–150, 1995Google Scholar
  39. 39.
    Srivastava AK: Protein tyrosine phosphorylation in cardiovascular system. Mol Cell Biochem 149/150: 87–94, 1995Google Scholar
  40. 40.
    Wijetunge S, Hugher AP: Effect of platelet derived growth factor on voltage operated calcium channels in rabbit isolated ear artery cells. Br J Pharmacol 115: 534–538, 1995Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Ashok K. Srivastava
    • 1
  • Jean St-Louis
    • 2
  1. 1.Research Center, Hôtel-Dieu de Montréal, Department of MedicineUniversity of MontréalMontréalCanada
  2. 2.Research Center, St. Justine Hospital, Department of Obstetrics and GynecologyUniversity of MontréalMontréalCanada

Personalised recommendations